MM&M

Slynd birth control maker draws FDA letter for social post that omitted risk info

Spanish pharma company Exeltis, which markets birth-control pill Slynd, was recently cited by American regulators for a paid Facebook post that omitted side-effect information. The Food and Drug ...
MediaPost

Body Equity Comes To Birth Control In Slynd Campaign

Combining a message of equity for diverse female body types with a pitch for Slynd birth control pills, a YouTube video titled “Let’s Love Everybody,” has racked up nearly 39 million million views in ...
Business Wire

Exeltis USA, Inc. Sparks National Conversation About Health Equity, Inclusion and Body Positivity During Women’s Health Month with “Let’s Love Every Body” Campaign

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Exeltis USA, Inc., a division of the global pharmaceutical group Insud Pharma, today announced “Let’s Love Every Body,” a national campaign designed to empower ...
RAPS

Facebook post prompts untitled letter to birth control maker Exeltis

The US Food and Drug Administration (FDA) recently sent Exeltis USA an untitled letter citing the company for a Facebook post promoting its birth control pill Slynd (drospirenone) without fully ...
FiercePharma

FDA blasts Exeltis over 'misleading' social media post about birth control drug

The FDA has torn into Exeltis over a social media sponsored post for birth control pill Slynd, lambasting the drugmaker for leaving out all the risk information, making misleading efficacy claims and ...